Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $287 Million - $383 Million
-1,387,263 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $57.4 Million - $68 Million
224,459 Added 19.3%
1,387,263 $377 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $100 Million - $132 Million
445,157 Added 62.03%
1,162,804 $338 Million
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $126 Million - $156 Million
630,909 Added 727.37%
717,647 $171 Million
Q4 2019

Feb 13, 2020

BUY
$166.71 - $223.91 $13.2 Million - $17.7 Million
78,933 Added 1011.31%
86,738 $19 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $67.3 Million - $75.8 Million
-405,059 Reduced 98.11%
7,805 $1.32 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $16.8 Million - $19.4 Million
-101,995 Reduced 19.81%
412,864 $75.6 Million
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $84.3 Million - $100 Million
514,859 New
514,859 $94.4 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Gqg Partners LLC Portfolio

Follow Gqg Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gqg Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gqg Partners LLC with notifications on news.